Akoya Biosciences showcases spatial biology 2.0 solutions at AACR meeting

Akoya Biosciences will highlight case studies featuring its Spatial Biology 2.0 Solutions that enable unprecedented speed and scale for spatial biology studies at the American Association for Cancer Research 2024 Annual Meeting in San Diego, April 5 to 10. In addition, the company will showcase new applications of its PhenoCode Signature Panels and preliminary data from the Thermo Fisher ViewRNA assays on Akoya’s platforms. Industry-leading capabilities of the company’s spatial biology platforms will be presented during Akoya’s Spotlight Theater, titled “Spatial Biology 2.0: Spatial Insights and Precision Medicine at Unprecedented Scale” on Monday, April 8 at 3 PM. The event will describe how researchers are revealing new insights into the tumor microenvironment, elucidating the mechanisms of cancer treatment response, and paving the way for spatial biology to impact patient outcomes. Deployment of Akoya’s PhenoCycler-Fusion 2.0, PhenoImager HT 2.0, and PhenoCode Panels across the research continuum, from ultrahigh-plex discoveries to actionable signatures, will be described by the presenters: Suzanne K. Coberly, MS MD, FCAP, Scientific Senior Director, Discovery & Translational Pathology, Oncogenesis TRC, Bristol Myers Squibb; Arutha Kulasinghe PhD, Scientific Director of the Queensland Spatial Biology Center in Brisbane, Group Leader at The University of Queensland; Pascal Bamford, PhD, Senior Vice President, R&D and Laboratory Operations, Akoya Biosciences. Dr. Kulasinghe will also present a talk entitled “Ultra high-plex profiling of the tumor microenvironment” on April 6 from 12:36 PM – 12:54 PM PT in Session MW14 – Choosing and Using Antibodies for Spatial Informed Protein Expression. He will discuss the development of ultrahigh-plex antibody panels for the comprehensive characterization of the tumor microenvironment. Akoya Biosciences will demonstrate new uses of its PhenoCode Signature Panels for accelerating discovery and validation of spatial biomarkers using the PhenoImager HT 2.0 platform. The company will also present initial findings from the Thermo Fisher Scientific ViewRNA assays on the PhenoCycler-Fusion 2.0. PhenoCycler-Fusion 2.0: Offers automated multi-slide capabilities, allowing researchers to efficiently generate ultrahigh-plex, multiomic spatial phenotyping data for larger samples at exceptional speeds. PhenoImager HT 2.0: Features targeted PhenoCode Signature Panels and onboard spectral unmixing, simplifying biomarker development and validation workflows for large scale studies.